content: <?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
    <headerData>
      <submissionType>144</submissionType>
      <filerInfo>
        <filer>
          <filerCredentials>
            <cik>0001859061</cik>
            <ccc>XXXXXXXX</ccc>
          </filerCredentials>
        </filer>
        <liveTestFlag>LIVE</liveTestFlag>
  
  
  
      </filerInfo>
    </headerData>
    <formData>
      <issuerInfo>
        <issuerCik>0001840439</issuerCik>
        <issuerName>BioMea Fusion Inc.</issuerName>
        <secFileNumber>001-40335</secFileNumber>
        <issuerAddress>
          <com:street1>826 Main Street</com:street1>
          <com:city>Redwood City</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94063</com:zipCode>
        </issuerAddress>
        <issuerContactPhone>650-980-9099</issuerContactPhone>
        <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>A2A Pharmaceuticals, Inc.</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
        <relationshipsToIssuer>
          <relationshipToIssuer>Stakeholder</relationshipToIssuer>
        </relationshipsToIssuer>
      </issuerInfo>
      <securitiesInformation>
        <securitiesClassTitle>Common</securitiesClassTitle>
        <brokerOrMarketmakerDetails>
          <name>UBS Financial Services Inc</name>
          <address>
            <com:street1>1000 Harbor Blvd</com:street1>
            <com:street2>3rd Floor</com:street2>
            <com:city>Weehawken</com:city>
            <com:stateOrCountry>NJ</com:stateOrCountry>
            <com:zipCode>07086</com:zipCode>
          </address>
        </brokerOrMarketmakerDetails>
        <noOfUnitsSold>400000</noOfUnitsSold>
        <aggregateMarketValue>12000000</aggregateMarketValue>
        <noOfUnitsOutstanding>35308622</noOfUnitsOutstanding>
        <approxSaleDate>04/27/2023</approxSaleDate>
        <securitiesExchangeName>NASDAQ</securitiesExchangeName>
      </securitiesInformation>
      <securitiesToBeSold>
        <securitiesClassTitle>Common</securitiesClassTitle>
        <acquiredDate>04/12/2021</acquiredDate>
        <natureOfAcquisitionTransaction>Pre-IPO   Owner</natureOfAcquisitionTransaction>
        <nameOfPersonfromWhomAcquired>BioMea Fusion Inc.</nameOfPersonfromWhomAcquired>
        <isGiftTransaction>N</isGiftTransaction>
        <amountOfSecuritiesAcquired>4363342</amountOfSecuritiesAcquired>
        <paymentDate>04/12/2021</paymentDate>
        <natureOfPayment>N/A</natureOfPayment>
      </securitiesToBeSold>
      <nothingToReportFlagOnSecuritiesSoldInPast3Months>N</nothingToReportFlagOnSecuritiesSoldInPast3Months>
      <securitiesSoldInPast3Months>
        <sellerDetails>
          <name>A2A Pharmaceuticals, Inc.</name>
          <address>
            <com:street1>8 Park Pl</com:street1>
            <com:city>Great Neck</com:city>
            <com:stateOrCountry>NY</com:stateOrCountry>
            <com:zipCode>11024</com:zipCode>
          </address>
        </sellerDetails>
        <securitiesClassTitle>COMMON</securitiesClassTitle>
        <saleDate>03/31/2023</saleDate>
        <amountOfSecuritiesSold>200000</amountOfSecuritiesSold>
        <grossProceeds>6233088</grossProceeds>
      </securitiesSoldInPast3Months>
      <securitiesSoldInPast3Months>
        <sellerDetails>
          <name>A2A Pharmaceuticals, Inc</name>
          <address>
            <com:street1>8 Park Pl</com:street1>
            <com:city>Great Neck</com:city>
            <com:stateOrCountry>NY</com:stateOrCountry>
            <com:zipCode>11024</com:zipCode>
          </address>
        </sellerDetails>
        <securitiesClassTitle>Common</securitiesClassTitle>
        <saleDate>04/20/2023</saleDate>
        <amountOfSecuritiesSold>200000</amountOfSecuritiesSold>
        <grossProceeds>5618000</grossProceeds>
      </securitiesSoldInPast3Months>
      <noticeSignature>
        <noticeDate>04/27/2023</noticeDate>
        <signature>/s/ UBS Financial Services Inc, as attorney-in-fact for A2A Pharmaceuticals, Inc.</signature>
      </noticeSignature>
    </formData>
  </edgarSubmission>
metadata_documents: [{"type": "144", "sequence": "1", "filename": "primary_doc.xml", "secsgml_size_bytes": 4009}]
text: 144
  0001859061
  XXXXXXXX
  LIVE
  0001840439
  BioMea Fusion Inc.
  001-40335
  826 Main Street
  Redwood City
  CA
  94063
  650-980-9099
  A2A Pharmaceuticals, Inc.
  Stakeholder
  Common
  UBS Financial Services Inc
  1000 Harbor Blvd
  3rd Floor
  Weehawken
  NJ
  07086
  400000
  12000000
  35308622
  04/27/2023
  NASDAQ
  Common
  04/12/2021
  Pre-IPO   Owner
  BioMea Fusion Inc.
  N
  4363342
  04/12/2021
  N/A
  N
  A2A Pharmaceuticals, Inc.
  8 Park Pl
  Great Neck
  NY
  11024
  COMMON
  03/31/2023
  200000
  6233088
  A2A Pharmaceuticals, Inc
  8 Park Pl
  Great Neck
  NY
  11024
  Common
  04/20/2023
  200000
  5618000
  04/27/2023
  /s/ UBS Financial Services Inc, as attorney-in-fact for A2A Pharmaceuticals, Inc.